OVULEN-21
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OVULEN-21 (OVULEN-21).
Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
| Metabolism | Hepatic via CYP3A4; ethinyl estradiol undergoes oxidation and conjugation; ethynodiol diacetate is metabolized to norethindrone. |
| Excretion | Renal: 50-60% as metabolites; fecal: 30-40% as conjugates; biliary excretion significant. |
| Half-life | Ethinyl estradiol: 13-27 hours (mean ~17 hours); norethindrone: 5-14 hours (mean ~8 hours); terminal half-life supports once-daily dosing. |
| Protein binding | Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 80-85% bound to albumin and SHBG. |
| Volume of Distribution | Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 2.3-3.4 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ethinyl estradiol 38-48%; norethindrone 64-70% (first-pass metabolism reduces bioavailability). |
| Onset of Action | Oral: 24 hours for ovulation suppression; 7 days for full contraceptive effect when started on day 1 of cycle. |
| Duration of Action | 24 hours; requires daily dosing to maintain contraceptive efficacy. |
One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment; use with caution in patients with impaired renal function. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class B or C); use not recommended. |
| Pediatric use | Not indicated for use before menarche. |
| Geriatric use | Not indicated for use after menopause. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OVULEN-21 (OVULEN-21).
| Breastfeeding | Excreted in breast milk. M/P ratio not established. Reduces milk production and quality. Use caution in nursing mothers; consider alternative contraception. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: Potential for feminization of male fetus, vaginal adenosis, and cervical ectropion. Also associated with increased risk of miscarriage and stillbirth. |
| Fetal Monitoring |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular side effects from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
| Serious Effects |
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast cancer; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; liver tumors or acute liver disease; hypersensitivity to components; smoking in women over 35.
| Precautions | Increased risk of thromboembolic disorders; hypertension; gallbladder disease; hepatic neoplasia; glucose intolerance; blood pressure monitoring recommended; discontinue if jaundice or visual disturbances occur. |
Loading safety data…
| Monitor for venous thromboembolism, hypertension, hepatic dysfunction, and glucose intolerance. Fetal ultrasound for congenital anomalies if exposed in first trimester. |
| Fertility Effects | Suppresses ovulation. Reversible upon discontinuation. No long-term impact on fertility. |